Examples of efforts by JPMA
Initiatives by AMED-Industry-Academia-Government Collaboration of antimicrobial agents
In September 2018, a liaison committee was established within the Japan Agency for Medical Research and Development (AMED) to investigate future strategic approaches in the field of infectious diseases and to further promote industry-academia-government collaboration. In order to exchange opinions about medical Needs in the field of infectious diseases and development trends of pharmaceutical companies with AMED and relevant academic societies (The Japanese Association for Infectious Diseases and Japanese Society of Chemotherapy), JPMA is participating in this liaison committee as representatives of the relevant pharmaceutical companies.
Initiatives with AMR Alliance Japan
Amid growing domestic and international interest in AMR, Health and Global Policy Institute, which has held expert meetings on AMR since 2016, has concluded that it is necessary to create an independent platform for multi-stakeholder discussions on AMR and to establish a cooperative system that has influence over AMR policy. In November 2018, the Health and Global Policy Institute established 「AMR Alliance Japan」by a multi-stakeholder in cooperation with eight national societies related to infectious diseases to improve public health through promotion of AMR measures.
JPMA is contributing to the progress of AMR policy and concrete implementation of measures as a member of AMR Alliance Japan.
https://www.amralliancejapan.org/en/
Activities of the Sub-committee on AMR of Asia Africa Medical Innovation Consortium (AMIC)
The Sub-committee on AMR was established in 2019 as part of AMIC which plan and implement a public private partnership(Public Private Partnership:P3) project throughout the year by the volunteering for the Nikkei FT Infectious Diseases Conference. The Sub-committee is held jointly by Nikkei Ltd. and AMR Alliance Japan (Secretariat: Health and Global Policy Institute), is held discussions to aim of proposing the industrial policies that lead to the sustainable research and development of antimicrobial agents with members of Industry-Academia-Government. JPMA participates in the activities of the Sub-committee on AMR as members of AMR Alliance Japan.
Antimicrobial resistance (AMR) action fund
The AMR action fund was established in July 2020 by more than 20 major biopharmaceutical companies as a revolutionary effort aimed at commercializing and delivering 2-4 new antimicrobial agents to patients by 2030. The Fund is an initiative of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) and JPMA contributes to the establishment of the Fund as a member organization of IFPMA and promotes advocacy activities.